日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma

雷帕霉素耐药的多克隆Th1/Tc1细胞疗法(RAPA-201)可安全地诱导复发难治性多发性骨髓瘤的疾病缓解。

Dhakal, Binod; Hari, Parameswaran; Chhabra, Saurabh; Szabo, Aniko; Lum, Lawrence G; Glass, Deborah D; Park, Jee Hyun; Donato, Michele; Siegel, David S; Felizardo, Tania C; Fowler, Daniel H

LAG3+ CD8+ T cell subset drives HR+/HER2- breast cancer reduction in bispecific antibody armed activated T cell therapy

LAG3+ CD8+ T 细胞亚群在双特异性抗体激活的 T 细胞疗法中驱动 HR+/HER2- 乳腺癌的减少

Barnes, Robert Weldon; Thakur, Archana; Onengut-Gumuscu, Suna; Lum, Lawrence G; Dolatshahi, Sepideh

Role of tankyrase scaffolding in the β-catenin destruction complex and WNT signaling

tankyrase支架在β-catenin破坏复合物和WNT信号通路中的作用

Wang, Qian; Li, Liping; You, Lin; Wang, Shuai; Han, Lei; Wang, Bingnan; Yao, Liping; Lu, Yong; Mender, Ilgen; Flusche, Ann M; Kim, Chiho; Yarravarapu, Nageswari; Lemoff, Andrew; Lum, Lawrence; Shay, Jerry W; Yu, Yonghao; Chen, Chuo

LAG3+ CD8+ T cell Subset Drives HR+/HER2- Breast Cancer Reduction in Bispecific Antibody Armed Activated T Cell Therapy

LAG3+ CD8+ T 细胞亚群驱动双特异性抗体武装活化 T 细胞疗法降低 HR+/HER2- 乳腺癌的发生率

Barnes, Robert Weldon; Thakur, Archana; Onengut-Gumuscu, Suna; Lum, Lawrence G; Dolatshahi, Sepideh

Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells

利用抗CD3×抗GD2双特异性抗体武装的T细胞靶向治疗难治性/复发性神经母细胞瘤和骨肉瘤

Yankelevich, Maxim; Thakur, Archana; Modak, Shakeel; Chu, Roland; Taub, Jeffrey; Martin, Alissa; Schalk, Dana; Schienshang, Amy; Whitaker, Sarah; Rea, Katie; Lee, Daniel W; Liu, Qin; Shields, Anthony F; Cheung, Nai-Kong V; Lum, Lawrence G

Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate-Resistant Prostate Cancer

转移性去势抵抗性前列腺癌患者对Sipuleucel-T治疗反应的种族差异

Heath, Elisabeth I; Thakur, Archana; Chen, Wei; Hwang, Clara; Paller, Channing J; Cackowski, Frank C; Boerner, Julie L; Heilbrun, Lance; Smith, Melanie P; Schalk, Dana L; Schienschang, Amy; Whitaker, Sarah A; Polend, Amanda; Smith, Daryn; Vaishampayan, Ulka N; Dickow, Brenda; Lum, Lawrence G

Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide

一项针对新诊断的 4 级星形细胞瘤的 I 期研究,采用双特异性抗体武装的 T 细胞(EGFR BATs)联合放疗和替莫唑胺治疗。

Fadul, Camilo E; Thakur, Archana; Kim, Jungeun; Kassay-McAllister, Jessica; Schalk, Dana; Lopes, M Beatriz; Donahue, Joseph; Purow, Benjamin; Dillon, Patrick; Le, Tri; Schiff, David; Liu, Qin; Lum, Lawrence G

Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer

帕博利珠单抗联合抗CD3×抗HER2双特异性抗体武装活化T细胞治疗转移性去势抵抗性前列腺癌的II期临床试验

Vaishampayan, Ulka N; Thakur, Archana; Chen, Wei; Deol, Abhinav; Patel, Meera; Dobson, Kimberlee; Dickow, Brenda; Schalk, Dana; Schienschang, Amy; Whitaker, Sarah; Polend, Amanda; Fontana, Joseph A; Heath, Elisabeth I; Lum, Lawrence G

Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells

利用抗CD3×抗GD2双特异性抗体武装的T细胞靶向GD2阳性难治性/耐药性神经母细胞瘤和骨肉瘤

Yankelevich, Maxim; Thakur, Archana; Modak, Shakeel; Chu, Roland; Taub, Jeffrey; Martin, Alissa; Schalk, Dana L; Schienshang, Amy; Whitaker, Sara; Rea, Katie; Lee, Daniel W; Liu, Qin; Shields, Anthony; Cheung, Nai-Kong; Lum, Lawrence G

Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia

针对急性髓系白血病的双特异性抗体靶向T细胞疗法

Kubicka, Ewa; Lum, Lawrence G; Huang, Manley; Thakur, Archana